Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1959 1
1961 1
1962 1
1964 1
1965 2
1966 1
1969 1
1970 1
1971 1
1973 1
1974 1
1975 1
1977 2
1978 6
1979 5
1980 6
1982 4
1983 3
1984 3
1985 2
1986 6
1987 1
1988 3
1989 4
1990 1
1991 4
1992 6
1993 5
1994 9
1995 12
1996 10
1997 21
1998 15
1999 22
2000 18
2001 17
2002 24
2003 34
2004 37
2005 48
2006 58
2007 63
2008 63
2009 89
2010 121
2011 145
2012 160
2013 192
2014 201
2015 232
2016 247
2017 285
2018 301
2019 370
2020 425
2021 533
2022 593
2023 625
2024 284

Text availability

Article attribute

Article type

Publication date

Search Results

4,765 results

Results by year

Filters applied: . Clear all
Page 1
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, Zhu J, Kong B, Fei J, Tang Y, Xia B, Liang Z, Wang K, Huang Y, Zheng H, Lin A, Jiang K, Wang W, Wang X, Lou G, Pan H, Yao S, Li G, Hao M, Cai Y, Chen X, Yang Z, Chen Y, Wen H, Qu P, Xu C, Hsieh CY; FLAMES Investigators. Wu X, et al. Among authors: wen h. Nat Med. 2024 May 15. doi: 10.1038/s41591-024-03003-9. Online ahead of print. Nat Med. 2024. PMID: 38750351
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.
Wu X, Zhu J, Yin R, Yang J, Liu J, Wang J, Wu L, Liu Z, Gao Y, Wang D, Lou G, Yang H, Zhou Q, Kong B, Huang Y, Chen L, Li G, An R, Wang K, Zhang Y, Yan X, Lu X, Lu W, Hao M, Wang L, Cui H, Chen Q, Abulizi G, Huang X, Tian X, Wen H, Huang Z, Dong J, Zhang C, Hou J, Mirza MR. Wu X, et al. Among authors: wen h. EClinicalMedicine. 2024 May 7;72:102629. doi: 10.1016/j.eclinm.2024.102629. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745967 Free PMC article.
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.
Liu HH, Xie Y, Yang BP, Wen HY, Yang PH, Lu JE, Liu Y, Chen X, Qu MM, Zhang Y, Hong WG, Li YG, Fu J, Wang FS. Liu HH, et al. Among authors: wen hy. Signal Transduct Target Ther. 2024 May 13;9(1):129. doi: 10.1038/s41392-024-01846-9. Signal Transduct Target Ther. 2024. PMID: 38740763 Free PMC article.
4,765 results